United Therapeutics CEO Exercises Options and Sells $5.26M in Shares via 10b5-1 Plan

Insider Filing Analysis: United Therapeutics Corp (NASDAQ: UTHR)

Executive Summary

On October 21, 2026, Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp, filed a Form 4 disclosing the exercise of stock options and subsequent sale of 9,500 shares of common stock on October 20, 2026. The sales generated aggregate gross proceeds of approximately $5.26 million at a weighted average price of $553.87 per share.

Key Transaction Details

• Nature of Transaction: Non-discretionary option exercise and stock sale under a Rule 10b5-1 trading plan established on November 7, 2025.
• Option Exercise: Exercised 9,500 options expiring on March 15, 2027, with an exercise price of $117.76 per share (aggregate exercise cost: $1,118,720).
• Sales Activity: 9,500 shares sold indirectly through a family trust across multiple tranches ranging from $546.26 to $564.04 per share, totaling $5,261,732.61 in gross sale value.
• Net Cash Flow: Net proceeds before taxes were approximately $4,143,012.61.

Post-Transaction Beneficial Ownership

Following the transactions, Dr. Rothblatt continues to hold substantial equity in United Therapeutics across direct and indirect holdings:

• Trust (subject to transaction): 324,443 shares
• Direct Ownership: 40,513 shares
• Other Family Trusts: 303,606 shares (249,108 + 45,596 + 8,902)
• Spouse: 166 shares
• Remaining Options in Trust: 195,410 stock options

Market Significance

The trading significance is assessed as Low. The transactions were fully automated under a pre-established Rule 10b5-1 plan entered into almost a year prior to execution. The sale represents the routine liquidation of expiring equity awards, and Dr. Rothblatt retains a substantial long-term equity position in the company.